Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 27, 2026

FullPAC, Inc. Issues Spring 2026 Chairman’s Letter

View original at globenewswire.com
FullPAC, Inc. Issues Spring 2026 Chairman’s Letter Virginia Beach, VA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- FullPAC, Inc. (“FullPAC” or the “Company”) (Nasdaq Reserved: GOTV), a premier nonpartisan campaign technology provider for more than 5,000 U.S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FullPAC is well positioned to serve the growing political spending market as campaign investment builds ahead of the 2028 Presidential election

    80% confidence

  • Advocacy Lab contributes meaningful recurring revenue and serves as a natural entry point into the broader FullPAC platform, strengthening client retention and expanding long-term revenue opportunities

    80% confidence

  • FullPAC is positioned to become the premier public-market pure play on America's growing political campaign industry

    80% confidence

  • Cash flows from Advocacy Lab will cover its direct purchase consideration by March 31, 2026, several months ahead of schedule

    80% confidence

  • Political campaign spending has surged ever higher since Citizens United was decided in 2010

    80% confidence

  • The 2026 election cycle's projected $10.8 billion advertising spending makes it the most expensive non-presidential election cycle in history, marking a more than 20% increase over 2022 midterms

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
FullPAC, Inc. Issues Spring 2026 Chairman’s Letter — Source | Via News | ViaNews Market